ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$19.95
· of 52w range
· above low
· to high
$19.5952w low
$30.9652w high
Market Cap (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Revenue (TTM)
$1.14B
your badges
52W Range
$20–$31
Analyst Rating
BUY
Price Target
$32
P/E
8.9
ROE
35.7%
Net Profit Margin
33.4%
Your badge strip is empty — pin a metric anywhere on this page.
ACAD Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$19.95
Market Cap (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Revenue (TTM)
$1.14B
ROE (TTM)
35.7%
52W Range
$20–$31
ACAD Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About ACADIA Pharmaceuticals Inc. - Common Stock Company overview from Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees796
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$1.07B2016-12-31 → 2025-12-31
EPS$2.302020-12-31 → 2025-12-31
Free Cash Flow$105M2016-12-31 → 2025-12-31
Net margin33.4%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ACAD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 8.95Y avg ≈-18.7 | ≈-18.7 | 13.8 | Undervalued | |
| P/S (TTM) | 3.05Y avg ≈5.5 | ≈5.5 | 11.9 | Undervalued | |
| P/B (MRQ) | 2.65Y avg ≈6.6 | ≈6.6 | 3.4 | Undervalued | |
| Price / FCF (TTM) | 23.65Y avg ≈64.0 | ≈64.0 | · | · | |
| Price / Cash Flow (TTM) | 21.45Y avg ≈63.4 | ≈63.4 | · | · | |
| Price / Tangible Book (MRQ) | 2.95Y avg ≈7.3 | ≈7.3 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ACAD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 7.6%5Y avg ≈-10.9% | ≈-10.9% | 12.5% | In line | |
| EBITDA Margin | 9.8%5Y avg ≈-10.9% | ≈-10.9% | 12.5% | In line | |
| Pretax Margin (TTM) | 10.7%5Y avg ≈-8.6% | ≈-8.6% | 16.4% | In line | |
| Net Profit Margin (TTM) | 33.4%5Y avg ≈-4.9% | ≈-4.9% | 10.2% | In line | |
| ROA (TTM) | 25.6%5Y avg ≈-2.7% | ≈-2.7% | -7.4% | Top tier | |
| ROE (TTM) | 35.7%5Y avg ≈-5.1% | ≈-5.1% | -10.7% | Top tier | |
| ROIC | 24.0%5Y avg ≈-11.4% | ≈-11.4% | -3.0% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ACAD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 3.45Y avg ≈3.8 | ≈3.8 | 6.5 | Low liquidity | |
| Quick Ratio | 1.15Y avg ≈1.4 | ≈1.4 | 5.0 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ACAD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 11.9%5Y avg ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y | 27.5%5Y avg ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | |
| EPS YoY | 69.1% | · | · | · | |
| Net Income YoY | 72.7% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ACAD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.85Y avg ≈0.9 | ≈0.9 | 0.4 | Top tier | |
| Inventory Turnover | 0.95Y avg ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover | 9.75Y avg ≈9.1 | ≈9.1 | 10.5 | In line | |
| Revenue / Employee | ≈$1.3M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
228.8%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 11, 2026 | $0.18 | $0.06 | 207.2% |
| March 31, 2026 | May 13, 2026 | $0.02 | $0.06 | -68.4% |
| Dec. 31, 2025 | $1.60 | $0.14 | 1044.5% | |
| Sept. 30, 2025 | $0.42 | $0.15 | 178.1% | |
| June 30, 2025 | $0.16 | $0.14 | 14.4% | |
| March 31, 2025 | $0.11 | $0.11 | -3.2% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M |
| Gross Margin % | · | · | 94.3% | 98.0% | 97.8% |
| Operating Margin % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M |
| Diluted EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M |
Institutional owners (13F) 386 filers · $4.7B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
386
Value held
$4.7B
New positions
49
Exited positions
36
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 49 (-4 vs prior Q) | 36 (+8 vs prior Q) | 135 (+15 vs prior Q) | 115 (-7 vs prior Q) | +4.6M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1,085,696,471 | 42,912,904 | 23.31% | Shares |
| BlackRock, Inc. | $569,633,876 | 22,515,173 | 12.23% | Shares |
| VANGUARD GROUP INC | $404,762,192 | 15,153,957 | 8.69% | Shares |
| STATE STREET CORP | $229,628,164 | 9,076,212 | 4.93% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223,612,785 | 8,838,450 | 4.80% | Shares |
| RTW INVESTMENTS, LP | $180,756,457 | 7,144,524 | 3.88% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $145,822,875 | 5,763,750 | 3.13% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $93,482,749 | 3,694,988 | 2.01% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $84,977,229 | 3,358,129 | 1.82% | Shares |
| Palo Alto Investors LP | $72,461,629 | 2,864,096 | 1.56% | Shares |
| GOLDMAN SACHS GROUP INC | $65,276,910 | 2,580,115 | 1.40% | Shares |
| Qube Research & Technologies Ltd | $61,899,233 | 2,446,610 | 1.33% | Shares |
| Point72 Asset Management, L.P. | $61,559,150 | 2,433,168 | 1.32% | Shares |
| CITADEL ADVISORS LLC | $55,209,078 | 2,182,177 | 1.19% | Shares |
| Pictet Asset Management Holding SA | $50,146,450 | 1,983,198 | 1.08% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49,826,959 | 1,969,445 | 1.07% | Shares |
| MARSHALL WACE, LLP | $44,650,402 | 1,764,838 | 0.96% | Shares |
| D. E. Shaw & Co., Inc. | $42,957,806 | 1,697,937 | 0.92% | Shares |
| BRAIDWELL LP | $41,653,895 | 1,646,399 | 0.89% | Shares |
| NORGES BANK | $41,069,692 | 1,623,308 | 0.88% | Shares |
| Frazier Life Sciences Management, L.P. | $36,386,409 | 1,438,198 | 0.78% | Shares |
| NORTHERN TRUST CORP | $34,595,776 | 1,367,422 | 0.74% | Shares |
| Nuveen, LLC | $34,109,259 | 1,348,192 | 0.73% | Shares |
| Artisan Partners Limited Partnership | $33,525,890 | 1,325,134 | 0.72% | Shares |
| BANK OF AMERICA CORP /DE/ | $32,899,740 | 1,300,385 | 0.71% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $32,449,679 | 1,282,596 | 0.70% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30,520,301 | 1,206,336 | 0.66% | Shares |
| Allspring Global Investments Holdings, LLC | $28,540,663 | 1,132,566 | 0.61% | Shares |
| Rockefeller Capital Management L.P. | $25,690,127 | 1,015,420 | 0.55% | Shares |
| MORGAN STANLEY | $23,949,976 | 946,639 | 0.51% | Shares |
| TWO SIGMA INVESTMENTS, LP | $23,452,898 | 926,992 | 0.50% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $23,082,961 | 912,370 | 0.50% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21,642,506 | 855,435 | 0.46% | Shares |
| Invesco Ltd. | $20,504,689 | 810,462 | 0.44% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $19,966,658 | 789,196 | 0.43% | Shares |
| Bank of New York Mellon Corp | $19,243,919 | 760,629 | 0.41% | Shares |
| Allianz Asset Management GmbH | $19,157,034 | 757,195 | 0.41% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $17,985,922 | 710,906 | 0.39% | Shares |
| Fisher Asset Management, LLC | $17,690,535 | 699,230 | 0.38% | Shares |
| FRED ALGER MANAGEMENT, LLC | $16,409,858 | 648,611 | 0.35% | Shares |
| RICE HALL JAMES & ASSOCIATES, LLC | $15,657,841 | 618,887 | 0.34% | Shares |
| AMERIPRISE FINANCIAL INC | $15,348,144 | 606,536 | 0.33% | Shares |
| MILLENNIUM MANAGEMENT LLC | $14,925,077 | 589,924 | 0.32% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14,771,456 | 583,852 | 0.32% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $13,225,551 | 522,749 | 0.28% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12,903,000 | 510,000 | 0.28% | Shares |
| GLENMEDE TRUST CO NA | $12,360,212 | 488,546 | 0.27% | Shares |
| Hudson Bay Capital Management LP | $11,764,500 | 465,000 | 0.25% | Shares |
| UBS Group AG | $11,639,341 | 460,053 | 0.25% | Shares |
| JUPITER ASSET MANAGEMENT LTD | $11,599,190 | 458,466 | 0.25% | Shares |
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 filings | Feb. 26, 2026 | 25.40% | Amendment | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 filings | June 6, 2013 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | May 2, 2005 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | May 2, 2005 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | May 2, 2005 | · | Initial filing | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | April 29, 2005 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 42 insiders · 24 officers · 21 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | March 24, 2026 M | 14,803 | 0 | 1 | $-249,932 |
| Stephen Davis | CEO | Aug. 19, 2024 S | 186,555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | Feb. 17, 2015 M | 115,549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Aug. 6, 2026 M | 67,828 | 0 | 9 | $-1,126,027 |
| Elena Ridloff | EVP and CFO | April 29, 2021 M | 10,553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | Oct. 15, 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | April 4, 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | Nov. 21, 2022 M | 61,234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | June 16, 2006 S | 317,756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | Nov. 17, 2024 M | 62,105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | July 29, 2026 M | 18,994 | 0 | 3 | $-506,411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | June 26, 2026 S | 13,088 | 0 | 8 | $-602,789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | March 24, 2026 M | 11,280 | 0 | 2 | $-245,022 |
| Thomas Garner | EVP, Chief Commercial Officer | March 6, 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | Jan. 6, 2024 M | 46,901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | Feb. 10, 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | Jan. 6, 2021 M | 8,059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | Oct. 15, 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | April 18, 2018 A | 83,734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | March 8, 2017 A | 1,671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | March 20, 2015 A | 18,550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | July 8, 2009 M | 20,000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | March 7, 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | March 11, 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Director | May 29, 2026 A | 32,908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Director | May 29, 2026 A | 33,489 | 0 | 0 | $0 |
| Jonathan Poole | Director | May 29, 2026 A | 2,010 | 0 | 0 | $0 |
| James M Daly | Director | May 29, 2026 A | 12,148 | 0 | 1 | $-671,100 |
| Laura Brege | Director | May 29, 2026 A | 23,202 | 0 | 0 | $0 |
| Edmund Harrigan | Director | May 29, 2026 A | 43,148 | 0 | 0 | $0 |
| Daniel B Soland | Director | May 29, 2025 A | 44,041 | 0 | 0 | $0 |
| Mary Ann Gray | Director | June 7, 2016 M | 149,476 | 0 | 0 | $0 |
| Leslie L Iversen | Director | April 18, 2016 M | 36,127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Director | Aug. 11, 2015 M | 17,000 | 0 | 0 | $0 |
| William Mcdowall Wells | Director | June 15, 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Director | June 15, 2015 A | 8,500 | 0 | 0 | $0 |
| Michael T Borer | Director | June 15, 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Director | June 12, 2009 A | 14,364 | 0 | 0 | $0 |
| Alan G Walton | Director | June 12, 2009 A | 25,979 | 0 | 0 | $0 |
| Martien Van Osch | Director | June 10, 2005 A | 1,168,892 | 0 | 0 | $0 |
| GORDON CARL L | Director | April 20, 2005 A | 774,006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | Oct. 20, 2008 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 59 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 4.92% | 13,265 SH | Sept. 11, 2026 | Daily |
| PBE · Invesco Exchange-Traded Fund Trust | 1.82% | 383,853 SH | Oct. 1, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.69% | 64,350 NS | July 31, 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1.40% | 124,236 SH | Oct. 1, 2026 | Daily |
| RZG · Invesco Exchange-Traded Fund Trust | 0.97% | 57,480 SH | Oct. 1, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.71% | 134,777 NS | July 31, 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0.62% | 14,725 NS | July 31, 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.35% | 150,827 SH | Aug. 19, 2026 | Daily |
| IBB · iShares Trust | 0.35% | 1,293,913 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.24% | 1,215,092 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.23% | 12,181 SH | Oct. 1, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.20% | 1,841 NS | July 31, 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.19% | 137,860 SH | Aug. 19, 2026 | Daily |
| BKSE · BNY Mellon ETF Trust | 0.19% | 6,256 NS | July 31, 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0.17% | 19,976 SH | Oct. 1, 2026 | Daily |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.17% | 443,221 SH | Aug. 19, 2026 | Daily |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.16% | 36,279 NS | July 31, 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.13% | 34,493 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.12% | 3,296,450 SH | Sept. 11, 2026 | Daily |
| ISCG · iShares Trust | 0.12% | 40,348 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.11% | 140,676 SH | Oct. 1, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.10% | 741,237 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.09% | 559,090 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.09% | 1,699,377 SH | Aug. 19, 2026 | Daily |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.08% | 40,712 NS | July 31, 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0.05% | 52,423 SH | Oct. 1, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.05% | 10,893 NS | July 31, 2026 | N-PORT |
| SMDX · Tidal Trust III | 0.05% | 2,295 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.04% | 54,681 NS | July 31, 2026 | N-PORT |
| IEUS · iShares Trust | 0.04% | 7,263 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.04% | 1,457,036 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.04% | 2,944,095 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.04% | 346,329 SH | Aug. 19, 2026 | Daily |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.04% | 13,154 SH | Oct. 1, 2026 | Daily |
| WSML · iShares Trust | 0.04% | 11,751 SH | Sept. 11, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 4,009 SH | Oct. 1, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.02% | 5,018 NS | July 31, 2026 | N-PORT |
| ISCF · iShares Trust | 0.02% | 13,099 SH | Sept. 11, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.02% | 113,182 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 348,929 NS | July 31, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.02% | 103,974 NS | July 31, 2026 | N-PORT |
| SCZ · iShares Trust | 0.02% | 238,968 SH | Sept. 9, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.01% | 16,150 NS | July 31, 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.01% | 28,150 SH | Aug. 19, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.01% | 39,121 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 35,516 SH | Sept. 10, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 161,527 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 35,634 NS | July 31, 2026 | N-PORT |
| IEFA · iShares Trust | 0.00% | 240,578 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.00% | 632 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 4,075,731 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 100,076 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 10,781 SH | Aug. 19, 2026 | Daily |
| IJR · iShares Trust | · | 7,728,763 SH | Sept. 10, 2026 | Daily |
| IJT · iShares Trust | · | 1,198,794 SH | Sept. 9, 2026 | Daily |
| XJR · iShares Trust | · | 17,544 SH | Aug. 31, 2026 | Daily |
| ISCB · iShares Trust | · | 5,636 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 221,806 SH | Sept. 11, 2026 | Daily |
| SMMV · iShares Trust | · | 16,924 SH | Aug. 19, 2026 | Daily |
ACAD Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 27 analysts
BUY
Median target
$33.00
+65.4%
7 25.9%
Strong Buy
14 51.9%
Buy
5 18.5%
Hold
1 3.7%
Sell
0 0.0%
Strong Sell
12-Month Price Target
19 analysts · 2026-09-29Mean target $32.16 +61.2%
Now
Current price $19.95
Low$17.00
Mean$32.16
High$49.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
BLUECHIP_DIP
Expired
risk 1
reward 5.00
entry
$21.20
R:R 5.00
BLUECHIP_DIP
Stopped out
risk 1
reward 4.79
entry
$21.86
R:R 4.79
BLUECHIP_DIP
Stopped out
risk 1
reward 4.99
entry
$22.45
R:R 4.99
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026